Company: IMNN
Filing Date: 2025-05-30
Form Type: 8-K
Source: 0001641172-25-013051
Chunk: 1

Company: Imunon, Inc.
Filing Date: 2025-05-30
Form: 8-K
Item: Item 3.01
Chunk 1
---
 June 6, 2025, and the Company’s common stock will be delisted from Nasdaq.

The
Company intends to request a hearing before the Panel at which it will request a suspension of delisting pending its return to compliance.
Pursuant to Nasdaq Listing Rule 5815(a)(1)(B), the Company expects that its hearing request will stay the suspension of trading and delisting
of the common stock pending the conclusion of the hearing process. Hearings are typically scheduled to occur approximately 30-45 days
after the date of the hearing request. Consequently, the Company expects the common stock to remain listed on Nasdaq at least until the
Panel renders a decision following the hearing.

The
Company intends to provide a plan to regain compliance to the Panel, including, subject to approval of the Company’s Board of Directors
and its stockholders, implementing a reverse stock split, should it be necessary.

There
can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in
compliance with other applicable Nasdaq listing rules, that the Company will be able to successfully implement a reverse stock split
if it decides to pursue one, that the Panel will grant the Company’s request for a suspension of delisting on Nasdaq, or that the
Company’s appeal of the delisting determination will be successful.

If
the Company’s securities are delisted from Nasdaq, it could be more difficult to buy or sell the Company’s common stock or
to obtain accurate quotations, and the price of the Company’s common stock could suffer a material decline. Delisting could also
impair the Company’s ability to raise capital and/or trigger defaults and penalties under outstanding agreements or securities
of the Company.

Except
for the factual statements made herein, information contained in this report consists of forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that are difficult to predict,
including statements regarding the Company’s plans to appeal the Nasdaq delisting determination, the Company’s ability to
regain compliance with Nasdaq’s continued listing requirements, the timing of the hearing and of the decision of the Panel, and
the outcome of the hearing. Words such as “will,” “believes,” “intends,” “expects,” “plans,”
and similar expressions, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement
is not forward